|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAPK7 |
Gene summary for MAPK7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAPK7 | Gene ID | 5598 |
| Gene name | mitogen-activated protein kinase 7 | |
| Gene Alias | BMK1 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024QZ20 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5598 | MAPK7 | LZE4T | Human | Esophagus | ESCC | 3.03e-03 | 1.02e-01 | 0.0811 |
| 5598 | MAPK7 | LZE24T | Human | Esophagus | ESCC | 3.06e-11 | 2.33e-01 | 0.0596 |
| 5598 | MAPK7 | P1T-E | Human | Esophagus | ESCC | 2.41e-07 | 3.63e-01 | 0.0875 |
| 5598 | MAPK7 | P2T-E | Human | Esophagus | ESCC | 1.65e-10 | 1.77e-01 | 0.1177 |
| 5598 | MAPK7 | P4T-E | Human | Esophagus | ESCC | 4.11e-06 | 1.17e-01 | 0.1323 |
| 5598 | MAPK7 | P8T-E | Human | Esophagus | ESCC | 5.87e-06 | 1.49e-01 | 0.0889 |
| 5598 | MAPK7 | P9T-E | Human | Esophagus | ESCC | 7.67e-08 | 1.10e-01 | 0.1131 |
| 5598 | MAPK7 | P10T-E | Human | Esophagus | ESCC | 1.30e-15 | 2.87e-01 | 0.116 |
| 5598 | MAPK7 | P11T-E | Human | Esophagus | ESCC | 3.10e-10 | 3.96e-01 | 0.1426 |
| 5598 | MAPK7 | P12T-E | Human | Esophagus | ESCC | 8.08e-19 | 2.91e-01 | 0.1122 |
| 5598 | MAPK7 | P15T-E | Human | Esophagus | ESCC | 7.19e-09 | 1.04e-01 | 0.1149 |
| 5598 | MAPK7 | P16T-E | Human | Esophagus | ESCC | 4.12e-11 | 1.98e-01 | 0.1153 |
| 5598 | MAPK7 | P17T-E | Human | Esophagus | ESCC | 5.97e-05 | 2.65e-01 | 0.1278 |
| 5598 | MAPK7 | P20T-E | Human | Esophagus | ESCC | 6.13e-11 | 2.01e-01 | 0.1124 |
| 5598 | MAPK7 | P21T-E | Human | Esophagus | ESCC | 9.02e-11 | 2.14e-01 | 0.1617 |
| 5598 | MAPK7 | P22T-E | Human | Esophagus | ESCC | 4.41e-07 | 1.30e-01 | 0.1236 |
| 5598 | MAPK7 | P23T-E | Human | Esophagus | ESCC | 7.41e-07 | 2.09e-01 | 0.108 |
| 5598 | MAPK7 | P24T-E | Human | Esophagus | ESCC | 1.47e-03 | 1.10e-01 | 0.1287 |
| 5598 | MAPK7 | P26T-E | Human | Esophagus | ESCC | 3.62e-03 | 1.25e-01 | 0.1276 |
| 5598 | MAPK7 | P27T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.04e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
| GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
| GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
| GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
| GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
| GO:2001236111 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway | 111/8552 | 151/18723 | 2.97e-12 | 1.18e-10 | 111 |
| GO:2001243111 | Esophagus | ESCC | negative regulation of intrinsic apoptotic signaling pathway | 78/8552 | 98/18723 | 5.50e-12 | 2.10e-10 | 78 |
| GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
| GO:0043618111 | Esophagus | ESCC | regulation of transcription from RNA polymerase II promoter in response to stress | 42/8552 | 47/18723 | 3.91e-10 | 1.05e-08 | 42 |
| GO:0043620111 | Esophagus | ESCC | regulation of DNA-templated transcription in response to stress | 46/8552 | 53/18723 | 5.17e-10 | 1.33e-08 | 46 |
| GO:0042542111 | Esophagus | ESCC | response to hydrogen peroxide | 102/8552 | 146/18723 | 2.64e-09 | 5.81e-08 | 102 |
| GO:0008631110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to oxidative stress | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
| GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
| GO:00715599 | Esophagus | ESCC | response to transforming growth factor beta | 157/8552 | 256/18723 | 2.95e-07 | 4.23e-06 | 157 |
| GO:2001237111 | Esophagus | ESCC | negative regulation of extrinsic apoptotic signaling pathway | 69/8552 | 97/18723 | 3.23e-07 | 4.55e-06 | 69 |
| GO:00703018 | Esophagus | ESCC | cellular response to hydrogen peroxide | 68/8552 | 98/18723 | 1.70e-06 | 2.03e-05 | 68 |
| GO:00715609 | Esophagus | ESCC | cellular response to transforming growth factor beta stimulus | 151/8552 | 250/18723 | 1.78e-06 | 2.10e-05 | 151 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0465734 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAPK7 | SNV | Missense_Mutation | c.715N>C | p.Tyr239His | p.Y239H | Q13164 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAPK7 | SNV | Missense_Mutation | c.671N>T | p.Thr224Met | p.T224M | Q13164 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MAPK7 | SNV | Missense_Mutation | rs748090158 | c.1502C>A | p.Ala501Asp | p.A501D | Q13164 | protein_coding | tolerated_low_confidence(0.17) | possibly_damaging(0.543) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| MAPK7 | SNV | Missense_Mutation | rs748090158 | c.1502N>A | p.Ala501Asp | p.A501D | Q13164 | protein_coding | tolerated_low_confidence(0.17) | possibly_damaging(0.543) | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| MAPK7 | SNV | Missense_Mutation | rs201284087 | c.502N>T | p.Arg168Trp | p.R168W | Q13164 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAPK7 | SNV | Missense_Mutation | c.775N>T | p.Arg259Cys | p.R259C | Q13164 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| MAPK7 | SNV | Missense_Mutation | c.1754C>T | p.Ser585Phe | p.S585F | Q13164 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAPK7 | SNV | Missense_Mutation | novel | c.160N>A | p.Glu54Lys | p.E54K | Q13164 | protein_coding | tolerated(0.38) | possibly_damaging(0.845) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAPK7 | SNV | Missense_Mutation | novel | c.1819N>T | p.Pro607Ser | p.P607S | Q13164 | protein_coding | tolerated(0.44) | benign(0) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| MAPK7 | SNV | Missense_Mutation | novel | c.2129T>C | p.Val710Ala | p.V710A | Q13164 | protein_coding | deleterious(0) | benign(0.107) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | TG02, SB1317 | |||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 328083508 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | sorafenib | SORAFENIB | 20124951 | |
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 249565744 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 381118893 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | XMD8-85 | CHEMBL1673039 | 21412406 | |
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 249565737 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 328083482 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |